(24/7 MARKET NEWS) – Biophytis SA (NASDAQ: BPTS) stated that it’s presenting the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at this weekend’s European Respiratory Society 2023 21st Lung Science Conference.
Biophytis is trading at $0.61, up $0.11 (+22.50%), on 1.5 million premarket shares.
Its 52-week trading range is $0.3501 to $3.36. Its premarket high is $0.8527 and it made a big move last week, so trading above the 65-cent level in the regular session would be bullish.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
